TY - JOUR
T1 - Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency-Related Loss of Heterozygosity
AU - Zhou, Alice
AU - Butt, Omar
AU - Ansstas, Michael
AU - Mauer, Elizabeth
AU - Khaddour, Karam
AU - Ansstas, George
N1 - Publisher Copyright:
© 2023 JNCCN-Journal of the National Comprehensive Cancer Network.
PY - 2023/7
Y1 - 2023/7
N2 - There is a lack of effective treatments for immunotherapy-refectory melanoma. Although PARP inhibitors (PARPi) are an effective treatment strategy in cancers with homologous recombination deficiency (HRD), determining HRD status is challenging in melanoma. Here, we chart the longitudinal relationship between PARPi response and HRD scores derived from genome-wide loss of heterozygosity (LOH) in 4 patients with metastaticmelanoma. When next examining 933 melanoma cases, using an updated threshold, we observed HRD-related LOH (HRD-LOH) in nearly one-third of all cases compared with ,10% using traditional gene panels. Taken together, HRD-LOH in refractory melanoma is both a common occurrence and a potential biomarker for response to PARPi.
AB - There is a lack of effective treatments for immunotherapy-refectory melanoma. Although PARP inhibitors (PARPi) are an effective treatment strategy in cancers with homologous recombination deficiency (HRD), determining HRD status is challenging in melanoma. Here, we chart the longitudinal relationship between PARPi response and HRD scores derived from genome-wide loss of heterozygosity (LOH) in 4 patients with metastaticmelanoma. When next examining 933 melanoma cases, using an updated threshold, we observed HRD-related LOH (HRD-LOH) in nearly one-third of all cases compared with ,10% using traditional gene panels. Taken together, HRD-LOH in refractory melanoma is both a common occurrence and a potential biomarker for response to PARPi.
UR - http://www.scopus.com/inward/record.url?scp=85164436728&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2022.7102
DO - 10.6004/jnccn.2022.7102
M3 - Article
C2 - 37433433
AN - SCOPUS:85164436728
SN - 1540-1405
VL - 21
SP - 688
EP - 693
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 7
ER -